In the context of resectable NSCLC, treatment with NAC was associated with increased numbers of CD8+CD103+ and CD4+CD103+PD‐1+TIM3− TRM cells in the TME and promoted antitumor immunity.218. This evidence concerns the gene CD8A and non-small cell lung carcinoma.